Speakers: Michiel Van der Heijden and Ignacio Durán Martínez
Michiel Van der Heijden and Ignacio Durán Martínez share their thoughts on the use of maintenance therapy after first-line chemotherapy for metastatic urothelial cancer and discuss new strategies in first line, such as single agent immunotherapy compared with chemotherapy and chemo-immuno combinations. They also comment on the upcoming results of the CheckMate 901 trial of nivolumab plus ipilimumab versus chemotherapy and highlight EV-302 study of enfortumab vedotin plus pembrolizumab compared with chemotherapy (21:23).
This independent programme is supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany